Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression

Pathology

Volumn 43, Issue 7, 2011, Pages 719-724

  Kayser, Gian ^a   Sienel, Wulf ^a   Kubitz, Britta ^a   Mattern, Dominik ^a   Stickeler, Elmar ^a   Passlick, Bernward ^a   Werner, Martin ^a   Hausen, Axel Zur ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Immunohistochemistry; Lung cancer; Metabolism; Prognosis; Transketolase L1

Indexed keywords

EID: 84858208795     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32834c352b     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30.
2. Parkin DM, Bray FI, Devesa SS. Cancer burdeninthe year 2000. The global picture. Eur J Cancer 2001; 37 (Suppl 8): S4-66.
3. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004; 4: 707-17. (Pubitemid 39215069)
4. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-91. (Pubitemid 35266288)
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8. (Pubitemid 34438899)
6. Pelicano H, Martin DS, Xu RH, et al. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633-46. ̈ (Pubitemid 44187614)
7. Warburg O, Posener K, Negelein E. Uber den stoffwechsel der carcinom-zelle. Biochem Z 1924; 152: 309-44.
8. Garber K. Energy boost: the Warburg effect returns in a new theory of cancer. J Natl Cancer Inst 2004; 96: 1805-6. (Pubitemid 40081310)
9. Coy JF, Dressler D, Wilde J, et al. Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab 2005; 51: 257-73. (Pubitemid 40895125)
10. Boros LG, Puigjaner J, Cascante M, et al. Oxythiamine and dehydroepian-drosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 1997; 57: 4242-8. (Pubitemid 27413432)
11. Comin-Anduix B, Boren J, Martinez S, et al. The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. Eur J Biochem 2001; 268: 4177-82. (Pubitemid 32862878)
12. Rais B, Comin B, Puigjaner J, et al. Oxythiamine and dehydroepiandros- terone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Lett 1999; 456: 113-8. (Pubitemid 29339052)
13. Schenk G, Duggleby RG, Nixon PF. Properties and functions of the thiamin diphosphate dependent enzyme transketolase. Int J Biochem Cell Biol 1998; 30: 1297-318. (Pubitemid 29002974)
14. Coy JF, Dubel S, Kioschis P, et al. Molecular cloning of tissue-specific transcripts of a transketolase-related gene: implications for the evolution of new vertebrate genes. Genomics 1996; 32: 309-16.
15. Langbein S, Zerilli M, Zur Hausen A, et al. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 2006; 94: 578-85. (Pubitemid 43289763)
16. Hu LH, Yang JH, Zhang DT, et al. The TKTL1 gene influences total transketolase activity and cell proliferation in human colon cancer LoVo cells. Anticancer Drugs 2007; 18: 427-33.
17. Zhang S, Yang JH, Guo CK, et al. Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett 2007; 253: 108-14. (Pubitemid 46874727)
18. Foldi M, Stickeler E, Bau L, et al. Transketolase protein TKTL1 over-expression: A potential biomarker and therapeutic target in breast cancer. Oncol Rep 2007; 17: 841-5.
19. Isidoro A, Casado E, Redondo A, et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 2005; 26: 2095-104. (Pubitemid 41672197)
20. Krockenberger M,Honig A, Rieger L, et al. Transketolase-like 1expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer 2007; 17: 101-6. (Pubitemid 46213977)
21. Robey IF, Lien AD, Welsh SJ, et al. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 2005; 7: 324-30. (Pubitemid 40664221)
22. Travis WD, Brambilla E, Mueller-Hermelink HK, et al. World Health Organization Classification of Tumours. Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
23. Hinze J. NCSS and PASS Number Cruncher Statistical Systems. Utah: Kashville; 2004.
24. Au NH, Cheang M, Huntsman DG, et al. Evaluation of immunohisto-chemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004; 204: 101-9. (Pubitemid 39214487)
25. Singhal S, Vachani A, Antin-Ozerkis D, et al. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005; 11: 3974-86. (Pubitemid 40791561)
26. Kayser G, Kassem A, Sienel W, et al. Lactate-dehydrogenase 5 is over-expressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol 2010; 5:
27. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-9. (Pubitemid 39472955)
28. Mayer A, Von Wallbrunn A, Vaupel P. Glucose metabolism of malignant cells is not regulated by transketolase-like (TKTL)-1. Int J Oncol 2010; 37: 265-71.
29. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-7. (Pubitemid 27260107)